Kneecapped by Aging: New and Scrutinized Science Suggests Why the UNITY Osteoarthritis Trial Failed
UNITY Biotechnology was the first senolytic startup out of the gate, and the failure of its Phase II trial in osteoarthritis was a crushing disappointment. A careful look back at the underlying science and three new scientific papers give us a good idea why and suggest ways to move forward.
